| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/ARD.2007.070847 |
| P698 | PubMed publication ID | 17519277 |
| P50 | author | Ian Bruce | Q30348366 |
| David A. Isenberg | Q42326409 | ||
| Caroline Gordon | Q58049734 | ||
| Munther A. Khamashta | Q73418907 | ||
| P2093 | author name string | A Rahman | |
| B Griffiths | |||
| A Zoma | |||
| P Maddison | |||
| C-S Yee | |||
| N McHugh | |||
| M Akil | |||
| D D'Cruz | |||
| K Sokoll | |||
| A Prabu | |||
| L-S Teh | |||
| P433 | issue | 6 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| lupus erythematosus | Q188297 | ||
| P304 | page(s) | 873-876 | |
| P577 | publication date | 2007-05-22 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000 | |
| P478 | volume | 67 |
| Q31142463 | A meta-analysis of public microarray data identifies gene regulatory pathways deregulated in peripheral blood mononuclear cells from individuals with Systemic Lupus Erythematosus compared to those without |
| Q35931154 | Analysis of Erythrocyte C4d to Complement Receptor 1 Ratio: Use in Distinguishing between Infection and Flare-Up in Febrile Patients with Systemic Lupus Erythematosus |
| Q84140353 | Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity |
| Q34494943 | Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus |
| Q37091322 | Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. |
| Q64983842 | Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells. |
| Q47573850 | Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study |
| Q36321563 | Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study |
| Q33386932 | Splenectomy for thrombocytopenia associated with systemic lupus erythematosus in 11 Chinese patients |
| Q36758822 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q40002833 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q34653846 | The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus. |
| Q33796222 | The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients |
| Q40910621 | The vascular phenotype of children with systemic lupus erythematosus |
| Q89883970 | Towards Precision Medicine in Systemic Lupus Erythematosus |
| Q34512800 | Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial |
| Q37236049 | Why can't we find a new treatment for SLE? |
Search more.